GoodRx Holdings, Inc. (GDRX) FY2026 Q2 P&L / Income Statement

GoodRx Holdings, Inc. (GDRX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

200,411,000 US dollars

Cost of revenue (calculated)

20,999,000 US dollars

Gross profit (calculated)

179,412,000 US dollars

Operating expenses (calculated)

155,780,000 US dollars

Operating income

23,632,000 US dollars

Total other expense, net

negative 8,166,000 US dollars

Income before income taxes

15,466,000 US dollars

Income tax expense

6,930,000 US dollars

Net income

8,536,000 US dollars

Prescription transactions revenue

106,390,000 US dollars

Subscription revenue

28,514,000 US dollars

Pharma Direct revenue

61,628,000 US dollars

Other revenue

3,879,000 US dollars

Cost of revenue, exclusive of depreciation and amortization presented separately below

20,999,000 US dollars

Product development and technology

26,711,000 US dollars

Sales and marketing

81,986,000 US dollars

General and administrative

24,814,000 US dollars

Depreciation and amortization

22,269,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.